Hepatitis C virus infection: The new global epidemic

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 2, 2005, Pages 241-249

  Butt, Adeel A ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Epidemiology; Hepatitis c; Hepatitis C virus; Hepatitis C virus transmission; Hepatitis C virus treatment; HIV

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; CD4 ANTIGEN; DIDANOSINE; ENZYME INHIBITOR; ERYTHROPOIETIN; HELICASE INHIBITOR; MESSENGER RNA; PEGINTERFERON ALPHA2A; PLACEBO; PROTEINASE INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

AFRICAN AMERICAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; CLINICAL FEATURE; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; ENZYME IMMUNOASSAY; EPIDEMIC; ETHNIC DIFFERENCE; FLU LIKE SYNDROME; GENETIC VARIABILITY; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION RISK; LACTIC ACIDOSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TOXICITY; LOW DRUG DOSE; MENTAL DISEASE; MOTHER CHILD RELATION; NEUTROPENIA; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SEXUAL TRANSMISSION; TERATOGENESIS; THROMBOCYTOPENIA; TREATMENT INDICATION; URINARY EXCRETION; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 17944383059     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.3.2.241     Document Type: Review

References (92)

1. Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C infection. Host, viral and environmental factors. J. Am. Med. Assoc. 284, 450-456 (2000).
2. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341(8), 556-562 (1999).
3. Centers for Disease Control and Prevention. Prevalence of hepatitis C virus infection among clients of HIV counseling and testing sites - Connecticut, 1999. Morb. Mortal. Wkly Rep. 50, 577-581 (2001).
4. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in HIV Atlanta VA (Veterans Affairs Medical Center) cohort study (HAVACS): the effect of coinfection on survival. Clin. Infect. Dis. 29, 150-154 (1999).
5. Austin GE, Jensen B, Leete J et al. Prevalence of hepatitis C virus seropositivity among hospitalized US veterans. Am. J. Med. Sci. 319(6), 353-359 (2000).
6. Briggs ME, Baker C, Hall R et al. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology 34(6), 1200-1205 (2001).
7. Schneeberger PM, Keur I, van Loon AM et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J. Infect. Dis. 182(5), 1291-1299 (2000).
8. Hayashi J, Yoshimura E, Nabeshima A et al. Seroepidemiology of hepatitis C virus infection in hemodialysis patients and the general population in Fukuoka and Okinawa, Japan. J. Gastroenterol. 29(3), 276-281 (1994).
9. Lamphear BP, Linnemann CC Jr, Cannon CG, DeRonde MM, Pendy L, Keley LM. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect. Control Hosp. Epidemiol. 15, 745-750 (1994).
10. Rischitelli G, Harris J, McCauley L, Gershon R, Guidotti T. The risk of acquiring hepatitis B or C among public safety workers. Am. J. Prev. Med. 20, 299-306 (2001).
11. Thorburn D, Dundas D, McCruden EA et al. A study of hepatitis C prevalence in healthcare workers in the west of Scotland. Gut 48(1), 116-120 (2001).
12. Balogun MA, Ramsay ME, Parry JV et al. The prevalence and genetic diversity of hepatitis C infection in antenatal clinic attenders in two regions of England. Epidemiol. Infect. 125, 705-712 (2000).
13. Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 31, 751-755 (2000).
14. Paternoster DM, Santarossa C, Grella P et al. Viral load in HCV RNA-positive pregnant women. Am. J. Gastroenterol. 96, 2751-2754 (2001).
15. Aslam MMD. Seroprevalence of the antibody to hepatitis C in select groups in the Punjab region of Pakistan. J. Clin. Gastroenterol. 33(5), 407-411 (2001).
16. Bari A. Risk factors for hepatitis C virus infection in male adults in Rawalpindi-Islamabad, Pakistan. Trop. Med. Int. Health 6(9), 732-738 (2001).
17. Darwish MA, Faris R, Darwish N et al. Hepatitis C and cirrhotic liver disease in the Nile Delta of Egypt: a community-based study. Am. J. Trop. Med. Hyg. 64, 147-153 (2001).
18. Nafeh MA, Medhat A, Shehta M et al. Hepatitis C in a community in upper Egypt. 1: cross-sectional survey. Am. J. Trop. Med. Hyg. 63, 236-241 (2000).
19. Darby SC, Ewart DW, Giangrande PL et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 350(9089), 1425-1431 (1997).
20. Khan AJ, Luby SP, Fikree F et al. Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan. Bull. World Health Organ. 78(8), 956-963 (2000).
21. Alter MJ, Coleman PJ, Alexander WJ et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. J. Am. Med. Assoc. 262(9), 1201-1205 (1989).
22. Luby SP, Qamruddin K, Shah AA et al. The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan. Epidemiol. Infect. 119(3), 349-356 (1997).
23. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 20, 1-16 (2000).
24. Farci P, Purcell RH. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin. Liver Dis. 20, 103-126 (2000).
25. Blackard JT, Yang Y, Bordoni P, Sherman KE, Chung RT. Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly act. antiretroviral therapy. J. Infect. Dis. 189(8), 1472-1481 (2004).
26. Fattovich G, Ribero ML, Pantalena M et al. Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe. J. Viral Hepat. 8, 206-216 (2001).
27. Memon MI, Memon MA. Hepatitis C: an epidemiological review. J. Viral Hepat. 9(2), 84-100 (2002).
28. Conry-Cantilena C, VanRaden M, Gibble J et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N. Engl. J. Med. 334, 1691-1696 (1996).
29. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markets and estimated window-period risk in the American Red Cross blood donor population. Transfusion 42(8), 975-979 (2002).
30. Orton SL, Stramer SL, Dodd RY, Alter MJ. Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV. Transfusion 44(2), 275-281 (2004).
31. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 43(6), 721-729 (2003).
32. Stramer SL, Glynn SA, Kleinman SH et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N. Engl. J. Med. 351, 760-768 (2004).
33. Chou R, Clark EC, Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the US Preventive Services Task Force. Ann. Intern. Med. 140(6), 465-479 (2004).
34. Alter MJ, Moyer LA. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 18(Suppl. 1), S6-S10 (1998).
35. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 18(SuppL 1), S11-S19 (1998).
36. Thorpe LE, Ouellet LJ, Levy JR, Williams IT, Monterroso ER. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999. J. Infect. Dis. 182(6), 1588-1594 (2000).
37. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am. J. Public Health 86(5), 655-661 (1996).
38. Everhart JE, Di Biseeglie AM, Murray LM et al. Risk for non-A, non-B (Type C) hepatitis through sexual or household contact with chronic carriers. Ann. Intern. Med. 112, 544-545 (1990).
39. Gordon SC, Patel AH, Kulesza GW, Barnes RE, Silverman AL. Lack of evidence for the heterosexual transmission of hepatitis C. Am. J. Gastroenterol. 87, 1849-1851 (1992).
40. Feldman JG, Minkoff H, Landesman S, Dehovitz J. Heterosexual transmission of hepatitis C, hepatitis B, and HIV-1 in a sample of inner-city women. Sex. Transm. Dis. 27, 338-342 (2001).
41. Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection. Diagnosis, natural history, meta-analysis sexual and vertical transmission and therapeutic issues. Arch. Intern. Med. 160, 3365-3373 (2000).
42. Granovsky MO, Minkoff HL, Tess BH et al. Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics 102, 355-359 (1998).
43. Yeung LTF, King SM, Roberts EA. Mother-to-infant transmission of Hepatitis C virus. Hepatology 34, 223-229 (2001).
44. Izopet J, Pasquier C, Sandres K, Puel J, Rostaing L. Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit. J. Med. Virol. 58(2), 139-144 (1999).
45. Esteban JI, Gomez J, Martell M et al. Transmission of hepatitis C virus by a cardiac surgeon. N. Engl. J. Med. 334(9), 555-560 (1996).
46. Ross RS, Viazov S, Roggendorf M. Risk of hepatitis C transmission from infected medical staff to patients: model-based calculations for surgical settings. Arch. Intern. Med. 160(15), 2313-2316 (2000).
47. Kiyosawa K, Sodeyama T, Tanaka E et al. Hepatitis C in hospital employees with needlestick injuries. Ann. Intern. Med. 115, 367-369 (1991).
48. Haley RW, Fischer RP. Commercial tattooing as a potentially important source of hepatitis C infection: clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine 80, 134-151 (2001).
49. Yerly S, Quadri R, Negro F et al. Nosocomial outbreak of multiple bloodborne viral infections. J. Infect. Dis. 184, 369-372 (2001).
50. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N. Engl. J. Med. 342, 1266-1271 (2000).
51. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology 27, 1213-1219 (1998).
52. Vrielink H, Zaaijier HL, Reesink HW, van der Poel CL, Cuypers HT, Lelie PN. Sensitivity and specificity of three third-generation anti-hepatitis C virus ELISAs. Vox Sang. 69, 14-17 (1995).
53. Atrah HI, Hutchinson F, Gough D, Ala FA, Ahmed MM. Hepatitis C virus seroconversion rate in established blood donors. J. Med. Virol. 46, 329-333 (1995).
54. Tong MJ, El Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 332(22), 1463-1466 (1995).
55. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morb. Mortal. Wkly Rep. 47, 1-39 (1998).
56. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peginoux M. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 27, 1717-1722 (1998).
57. Okazaki T, Yoshihara H, Suzuki K, Yamada Y, Tsujimura T, Kawano K. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between nondrinkers and drinkers. Scand. J. Gastroenterol. 29, 1039-1043 (1994).
58. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132(4), 296-305 (2000).
59. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am. J. Gastroenterol. 88, 240-243 (1993).
60. Wiley TE, McCarty M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 28, 805-809 (1998).
61. Mathurin P, Moussaili J, Cadranel JF et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 27, 868-872 (1998).
62. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Engl. J. Med. 340(16), 1228-1233 (1999).
63. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 32, 492-497 (2001).
64. Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Curr. Infect. Disease Reports 3, 469-476 (2001).
65. Yeo AE, Ghany M, Conry-Cantilena C et al. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J. Viral. Hepat. 8(4), 256-263 (2001).
66. Butt AA, Herrine S. Hepatitis C. In: Antimicrobial Therapy and Vaccines, Third Edition. Yu VL, Weber R, Raoult D (Eds). Apple Trees Productions, NY, USA (2002).
67. 2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343(23), 1673-1690 (2000).
68. Lee SS, Sherman M. Pilot study of interferon-α and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values. J. Viral Hepat. 8, 202-205 (2001).
69. Puoti C, Magrini A, Stati T et al. Clinical, histological, virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 26(6), 1393-1398 (1997).
70. 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 359, 958-965 (2001).
71. 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 359, 1485-1492 (1998).
72. 2b as initial treatment for chronic hepatitis C. Hepatology 34(2), 395-403 (2001).
73. 2b as initial treatment for chronic hepatitis C. Eur. J. Gastroenterol. Hepatol. 13(9), 1132 (2001).
74. 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352(9138), 1426-1432 (1998).
75. 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339(21), 1493-1499 (1998).
76. Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human α-interferon. A preliminary report. N. Engl. J. Med. 315(25), 1575-1578 (1986).
77. 2a in patients with chronic hepatitis C. N. Engl. J. Med. 343, 1666-1672 (2000).
78. 2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 351(5), 438-450 (2004).
79. 2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 351(5), 451-459 (2004).
80. 2b ribavirin/combination therapy in HCV/HIV coinfected persons. 1st IAS conference on HIV pathogenesis and treatment. Buenos Aires, Argentina, 7-11 July 2001 (Abstract 555).
81. 2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 14, 839-844 (2000).
82. 2b and tribavirin. AIDS 15(14), 1783-1787 (2001).
83. Perez-Olmeda M, Romero M, Asensi V, Sanchez-Montero F, Ochoa A, Garcia-Samaniego J. Efficacy and safety of combination therapy with interferon plus ribavirin in HIV-infected patients with chronic hepatitis C. 52nd Annual Meeting of the American Association for the Study of Liver Diseases. Dallas, TX USA. 9-13 November 2002 (Abstract 641).
84. 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 18(1), 67-73 (2004).
85. 2b and ribavirin in HIV /hepatitis C virus-coinfected nonresponders and relapsers to IFN-based therapy. AIDS 18(1), 75-79 (2004).
86. Ho SB, Ngyuen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E. Influence of psychiatric diagnoses on interferon-α treatment for chronic hepatitis C in a veteran population. Am. J. Gastroenterol. 96(1), 157-164 (2001).
87. Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J. Clin. Gastroenterol. 34(3), 268-271 (2002).
88. Sulkowski MS, Thomas DL, Mehra SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35(1), 182-189 (2002).
89. Butt AA. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. The AIDS Reader 13(7), 344-348 (2003).
90. 2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39(6), 1702-1708 (2004).
91. Bruchfeld A, Stable L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J. Viral Hepat. 8(4), 287-292 (2001).
92. Tan AC, Brouwer JT, Glue P et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol. Dial. Transplant. 16(1), 193-195 (2001).